Study design considerations for the Standardized Treatment Of Pulmonary exacerbations 2 (STOP2): a trial to compare intravenous antibiotic treatment durations in CF

摘要

BACKGROUNDPulmonary exacerbations (PEx) in cystic fibrosis (CF) are common and contribute to morbidity and mortality. Duration of IV antibiotic therapy to treat PEx varies widely in the US, and there are few data to guide treatment decisions.